Pharmaceutical companies launching an oncology product in the United States often face crowded markets and regulatory constraints. As more and more oncology products make their way through the development and approval process in the U.S., it is important for pharma companies to optimize their launch investment and staffing levels for key activities and functions before, during and post launch to ensure successful market entry.
Also, organizations often pursue a second indication for the same oncology product in order to not only expand a product's patient base but also to leverage savings on launch investment by using infrastructure and resources from the first indication launch.
Best Practices, LLC undertook benchmarking research to inform oncology launch teams with evidence-based benchmarks around investment, staffing and timing requirements to successfully launch new oncology drugs in the U.S. market.
In particular, the report benchmarks investment levels at each launch stage as well as budget and staffing allocation across critical Medical and Commercial activities for various market-entry situations or market-entry archetypes: portfolios featuring multiple molecules which treat single or multiple indications, and portfolios using single molecules to treat individual cancer types. It also probes key U.S. oncology market-entry trends and success factors and explores the synergy or franchise effects where multiple oncology products and indications create lift through shared infrastructure.